CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0579

Primobolan E

Filed under Injectable Oils. The bureau holds 136 laboratory returns for this compound from 42 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

42 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
HomopeptideCASE #VI-2026-0760 A 5 10.0 9.9 10.0 23 May 2026 23 May 2026
WuXi TIDESCASE #VI-2026-0335 A 5 10.0 9.9 10.0 8 Jan 2026 1 Jun 2026
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 4 10.0 9.9 10.0 14 Nov 2025 16 Apr 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 4 10.0 9.9 10.0 14 Jan 2026 21 May 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 4 10.0 9.9 10.0 5 Feb 2026 24 Jun 2026
PolyPeptide GroupCASE #VI-2026-0143 A 4 10.0 10.0 10.0 2 Jan 2026 6 Aug 2026
JEEP PeptidesCASE #VI-2026-0457 A 3 10.0 10.0 10.0 1 Feb 2026 25 May 2026
BachemCASE #VI-2026-0314 A 3 10.0 9.9 10.0 1 May 2026 2 Jul 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 3 10.0 9.9 10.0 9 Apr 2026 26 Jun 2026
QYAOBIOCASE #VI-2026-0861 A 2 10.0 10.0 10.0 11 Jan 2026 11 Jul 2026
Hubei JianxiangCASE #VI-2026-0048 A 2 10.0 10.0 10.0 21 Apr 2026 4 Jul 2026
AsymchemCASE #VI-2026-0091 A 2 10.0 10.0 10.0 16 Apr 2026 23 Apr 2026
Kerui PeptidesCASE #VI-2026-0626 A 4 9.9 9.9 10.0 21 Nov 2025 1 Jul 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 4 9.9 9.9 10.0 13 Jan 2026 11 Jul 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 4 9.9 9.9 10.0 27 Jan 2026 16 Jul 2026
AmbioPharmCASE #VI-2026-0177 A 4 9.9 9.9 10.0 18 Dec 2025 18 Jul 2026
Sigma-AldrichCASE #VI-2026-0829 A 3 9.9 9.9 10.0 27 Jun 2026 5 Aug 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 2 9.9 9.9 10.0 1 Feb 2026 5 Jul 2026
Sangon BioCASE #VI-2026-0671 A 2 9.9 9.9 9.9 9 Jan 2026 28 Apr 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 2 9.9 9.9 10.0 24 Mar 2026 6 Jul 2026
GenScript PeptidesCASE #VI-2026-0860 A 2 9.9 9.9 10.0 10 Jun 2026 25 Jun 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 2 9.9 9.9 9.9 1 Apr 2026 6 May 2026
SinoPepCASE #VI-2026-0387 A 2 9.9 9.9 9.9 17 Apr 2026 28 Jul 2026
The Naughty NeedleCASE #VI-2026-0432 X 1 9.1 9.1 9.1 16 Mar 2025 16 Mar 2025
Glbiochem (Shanghai)CASE #VI-2026-0704 A 3 8.8 8.3 9.1 23 May 2026 23 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 8 8.7 8.1 9.9 23 May 2026 23 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 6 8.5 7.3 9.4 23 May 2026 23 May 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 7 8.4 7.9 8.9 24 May 2026 24 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 8 8.2 7.0 9.2 24 May 2026 24 May 2026
Diju Peptides Wellness and CoCASE #VI-2026-0724 X 1 7.6 7.6 7.6 28 Mar 2025 28 Mar 2025
Bulk Peptide WholesaleCASE #VI-2026-0319 A 2 7.1 6.7 7.4 3 Jun 2025 21 May 2026
Reta-PeptideCASE #VI-2026-0756 X 14 6.8 5.8 8.9 21 May 2025 25 May 2026
Liberty PeptidesCASE #VI-2026-0416 X 1 6.8 6.8 6.8 21 May 2025 21 May 2025
Lisa BiopeptideCASE #VI-2026-0131 X 1 6.7 6.7 6.7 27 Feb 2025 27 Feb 2025
Heman Peptide HMCASE #VI-2026-0089 X 2 6.2 4.4 8.1 20 Jun 2025 21 May 2026
Atomik LabzCASE #VI-2026-0327 X 2 5.9 4.8 7.0 3 Jun 2025 24 May 2026
Swiss ChemsCASE #VI-2026-0030 X 1 5.8 5.8 5.8 6 May 2025 6 May 2025
Planet PeptideCASE #VI-2026-0092 X 1 5.0 5.0 5.0 21 May 2025 21 May 2025
Shanghai Wibson Biotechnology WBSCASE #VI-2026-0214 X 1 4.9 4.9 4.9 3 Jun 2025 3 Jun 2025
PurePeptidesCASE #VI-2026-0234 X 1 4.4 4.4 4.4 27 Feb 2025 27 Feb 2025
TydesCASE #VI-2026-0493 X 3 4.1 2.4 5.6 17 Dec 2024 17 May 2026
PepKitsCASE #VI-2026-0320 X 1 0.0 0.0 0.0 24 Apr 2025 24 Apr 2025

Open any subject to view the batch-level evidence for Primobolan E alone.